GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Societal CDMO Inc (FRA:RAH) » Definitions » EV-to-FCF

Societal CDMO (FRA:RAH) EV-to-FCF : -9.17 (As of Oct. 31, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Societal CDMO EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Societal CDMO's Enterprise Value is €79.23 Mil. Societal CDMO's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-8.64 Mil. Therefore, Societal CDMO's EV-to-FCF for today is -9.17.

The historical rank and industry rank for Societal CDMO's EV-to-FCF or its related term are showing as below:

FRA:RAH' s EV-to-FCF Range Over the Past 10 Years
Min: -71.93   Med: -6.74   Max: 1569.6
Current: -16.86

During the past 13 years, the highest EV-to-FCF of Societal CDMO was 1569.60. The lowest was -71.93. And the median was -6.74.

FRA:RAH's EV-to-FCF is not ranked
in the Drug Manufacturers industry.
Industry Median: 24.81 vs FRA:RAH: -16.86

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-10-31), Societal CDMO's stock price is €1.58. Societal CDMO's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.140. Therefore, Societal CDMO's PE Ratio (TTM) for today is At Loss.


Societal CDMO EV-to-FCF Historical Data

The historical data trend for Societal CDMO's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Societal CDMO EV-to-FCF Chart

Societal CDMO Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.32 361.72 28.39 -13.31 -7.68

Societal CDMO Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.31 -16.94 -14.19 -7.77 -7.68

Competitive Comparison of Societal CDMO's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Societal CDMO's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Societal CDMO's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Societal CDMO's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Societal CDMO's EV-to-FCF falls into.



Societal CDMO EV-to-FCF Calculation

Societal CDMO's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=79.233/-8.644
=-9.17

Societal CDMO's current Enterprise Value is €79.23 Mil.
Societal CDMO's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Societal CDMO  (FRA:RAH) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Societal CDMO's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.58/-0.140
=At Loss

Societal CDMO's share price for today is €1.58.
Societal CDMO's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.140.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Societal CDMO EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Societal CDMO's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Societal CDMO Business Description

Traded in Other Exchanges
N/A
Address
1 E. Uwchlan Avenue, Suite 112, Exton, PA, USA, 19341
Societal CDMO Inc is a bi-coastal contract development and manufacturing organization. It offers capabilities spanning pre-Investigational New Drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms primarily focused on small molecules. They have an expertise in solving complex manufacturing problems, the Company provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market.

Societal CDMO Headlines

No Headlines